Evidence map›Paper›PMID 42151443›Full record

ArticleMolecular psychiatry2026

Protective TMEM106B-rs3173615 delays age at onset in GRN mutation carriers.

Lorenzo Pagano, Claudia Saraceno, Andrea Geviti, Silvia Fostinelli, Alessandro Facconi, Valentina Laganà, Giulia Giacomucci, Maria Sofia Cotelli, Assunta Ingannato, Silvia Bagnoli and 11 more

Abstract read
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lorenzo Pagano *Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Claudia Saraceno *Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy. csaraceno@fatebenefratelli.eu.ORCID http://orcid.org/0000-0001-8618-4282
Andrea GevitiService of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Silvia FostinelliMAC-Memory Clinic and Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Alessandro FacconiMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Valentina LaganàRegional Neurogenetic Centre (CRN), Department of Primary Care, ASP Catanzaro, 88046, Lamezia Terme, Italy.
Giulia GiacomucciDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, 50139, Florence, Italy.
Maria Sofia CotelliDepartment of Continuity of Care and Frailty, ASST Spedali Civili di Brescia, 25123, Brescia, Italy.
Assunta IngannatoDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, 50139, Florence, Italy.
Silvia BagnoliDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, 50139, Florence, Italy.
Antonio LongobardiMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.ORCID http://orcid.org/0000-0002-8292-6434
Alice RussottoMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.ORCID http://orcid.org/0000-0002-6279-5983
Sonia BelliniMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Davide LagrotteriaDepartment of Biology, Ecology and Earth Sciences, University of Calabria, 87036, Rende, Italy.
Ersilia PaparazzoDepartment of Biology, Ecology and Earth Sciences, University of Calabria, 87036, Rende, Italy.
Giuliano BinettiMAC-Memory Clinic and Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Alberto MontesantoDepartment of Biology, Ecology and Earth Sciences, University of Calabria, 87036, Rende, Italy.
Benedetta NacmiasDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, 50139, Florence, Italy.ORCID http://orcid.org/0000-0001-9338-9040
Raffaele MalettaRegional Neurogenetic Centre (CRN), Department of Primary Care, ASP Catanzaro, 88046, Lamezia Terme, Italy.
Barbara BorroniMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy.
Roberta GhidoniMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125, Brescia, Italy. rghidoni@fatebenefratelli.eu.ORCID http://orcid.org/0000-0002-7691-1957

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the major causative genes involved in Frontotemporal dementia (FTD) is Granulin (GRN), encoding for Progranulin (PGRN). GRN mutation carriers show a substantial heterogeneity with high variability in age at onset and pathological presentation, even within the same family or identical mutations, suggesting the presence of additional genetic factors. Single nucleotide polymorphisms in the Transmembrane protein 106B (TMEM106B) locus were identified as a genetic risk-associated factor for FTD. The top variant identified was the non-coding rs1990622, with the major allele (T) associated with an increased risk to develop FTD, while subjects with the minor allele (C) were less likely to develop disease, suggesting a protective effect. In this study, we investigate in a large Italian cohort of GRN mutation carriers, how the coding variant TMEM106B-rs3173615, in linkage disequilibrium with rs1990622, modulates age at onset, survival, and PGRN levels, including, up to date, the highest sample size of homozygous protective allele carriers. Genetic screening for TMEM106B-rs3173615 was performed on a total of 187 GRN mutation carriers, comprising 131 FTD patients and 56 pre-symptomatic subjects. Individuals with the protective genotype (GG) had a risk of FTD onset reduced by 80%, with a median age at onset of 77 years compared to a median age at onset of 63 years for individuals without the protective genotype. TMEM106B-rs3173615 acts as a genetic modifier of age at onset in the presence of GRN mutations and could be considered in clinical practice to optimize risk stratification for FTD.

Indexed as

Frontotemporal DementiaIntercellular Signaling Peptides and ProteinsMembrane ProteinsNerve Tissue ProteinsAgedAge of OnsetAllelesCohort StudiesFemaleGenetic Predisposition to DiseaseGenotypeHeterozygoteHumansItalyLinkage DisequilibriumMaleGRN protein, humanIntercellular Signaling Peptides and ProteinsMembrane ProteinsNerve Tissue ProteinsProgranulinsTMEM106B protein, human

Identifiers

PMID42151443
PMCPMC13569440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.